EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Haemodynamic Effects of Istaroxime in SCAI Stage B HF-Related Cardiogenic Shock: Insights from the SEISMiC Trial

Matteo Pagnesi iD, Gad Cotter, Beth Davison, Daniel Burkhoff, Alexander Mebazaa, Jan Biegus, Ovidiu Chioncel, Christopher Edwards, Koji Takagi, Gerasimos Filippatos, Agnieszka Tycińska, Maria Novosadova und 10 weitere

ESC Heart Failure · 01.12.2025 · 12 (6) · 3966-3975

DOI: 10.1002/ehf2.15448 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift ESC Heart Failure, online erschienen am 14.10.2025. Verfasst von Matteo Pagnesi und 21 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia…. Hauptthemen laut MEDLINE: Shock, Cardiogenic, Heart Failure, Hemodynamics, Stroke Volume. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The haemodynamic effects of istaroxime in SCAI stage B cardiogenic shock (CS) due to acute decompensated heart failure (ADHF) have not been evaluated. We assessed the impact of istaroxime on specific invasively-obtained haemodynamic measures. Methods and results In the SEISMiC extension study, 30 patients with ADHF-related SCAI stage B CS were randomized to 60-h intravenous infusion of either placebo (n = 11) or istaroxime at maximum 0.5–1.0 μg/kg/min (n = 19). In this post hoc analysis, invasively-obtained haemodynamic measures, simulated group-averaged pressure-volume (PV) loops, and end-systolic elastance (Ees), derived from individual-patient PV relationships, were compared between istaroxime- and placebo-treated patients. Compared with placebo, patients randomized to istaroxime for 48–60 h had greater increases in aortic pulsatility index (API) and left ventricular (LV) stroke work index (LVSWI) at 6, 12, 24, and 48 h; and greater increase in pulmonary artery (PA) compliance and reduction in PA elastance at 48 h. At group-averaged PV loop analysis, LV contractility remained stable and right ventricular (RV) contractility tended to deteriorate over time with placebo, whereas LV contractility improved and RV contractility tended to be stabilized with istaroxime. Greater increases in both LV Ees and RV Ees were observed with istaroxime versus placebo from baseline to 48 h.

Conclusions

In patients with ADHF-pre-CS, istaroxime at doses up to 1.0 μg/kg/min for up to 60 h was associated with sustained improvements in measures of LV performance (API and LVSWI), in parallel with increase in PA compliance and reduction in PA elastance at 48 h. As compared with placebo, istaroxime improved LV contractility and preserved RV contractility, which deteriorated on placebo, over time.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Shock, CardiogenicHeart FailureHemodynamicsStroke VolumeVentricular Function, LeftHumansMaleFemaleAgedMiddle AgedDouble-Blind MethodInfusions, IntravenousTreatment OutcomeFollow-Up Studies

Stichwörter der Autor:innen

CalcitropeCardiogenic shockHaemodynamicsInotropeIstaroximePre‐cardiogenic shock

Autor:innen und Institutionen

  • Cardiology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
  • Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), Université Paris Cité, Paris, France.
  • Momentum Research, Inc, Durham, North Carolina, USA.
  • Cardiovascular Research Foundation, New York, New York, USA.
  • Department of Anesthesiology and Critical Care and Burn Unit, Saint-Louis and Lariboisière Hospitals, FHU PROMICE, DMU Parabol, APHP Nord, Paris, France.
  • Institute of Heart Diseases, Wroclaw Medical University, Wrocław, Poland.

ORCID-Profile: Matteo Pagnesi

Zitieren

APA

Pagnesi, M., Cotter, G., Davison, B., Burkhoff, D., Mebazaa, A., Biegus, J., Chioncel, O., Edwards, C., Takagi, K., Filippatos, G., Tycińska, A., Novosadova, M., Gulati, G., Barros, M., Diaz, M. L., Guardia, C., Zymliński, R., Gajewski, P., Ponikowski, P., …, & Metra, M. (2025). Haemodynamic Effects of Istaroxime in SCAI Stage B HF-Related Cardiogenic Shock: Insights from the SEISMiC Trial. ESC Heart Failure, 12(6), 3966-3975. https://doi.org/10.1002/ehf2.15448

Vancouver

Pagnesi M, Cotter G, Davison B, Burkhoff D, Mebazaa A, Biegus J, et al. Haemodynamic Effects of Istaroxime in SCAI Stage B HF-Related Cardiogenic Shock: Insights from the SEISMiC Trial. ESC Heart Failure. 2025;12(6):3966-3975. doi:10.1002/ehf2.15448

BibTeX
@article{Pagnesi2025,
  author = {Pagnesi, Matteo and Cotter, Gad and Davison, Beth and Burkhoff, Daniel and Mebazaa, Alexander and Biegus, Jan and Chioncel, Ovidiu and Edwards, Christopher and Takagi, Koji and Filippatos, Gerasimos and Tycińska, Agnieszka and Novosadova, Maria and Gulati, Gaurav and Barros, Marianela and Diaz, Maria Luz and Guardia, Carlos and Zymliński, Robert and Gajewski, Piotr and Ponikowski, Piotr and Simmons, Phillip and Simonson, Steven and Metra, Marco},
  title = {Haemodynamic Effects of Istaroxime in SCAI Stage B HF-Related Cardiogenic Shock: Insights from the SEISMiC Trial},
  journal = {ESC Heart Failure},
  year = {2025},
  volume = {12},
  number = {6},
  pages = {3966--3975},
  doi = {10.1002/ehf2.15448}
}
Kostenlos starten →